Liver Cancer Trial, Recruiting NCT07623265 Sponsor: Universitaire Ziekenhuizen KU Leuven Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT07623265
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older, of any sex
  • People who have been diagnosed with, or are suspected to have, a type of liver cancer called hepatocellular carcinoma (HCC), based on medical scans

For Group 1 (people with past treatment records — may include historical data):

  • People whose HCC was confirmed by a laboratory examination of tissue (pathology)
  • People who received a specific type of cancer medication (either a targeted therapy or immunotherapy) in the last 7 years, with at least one scan result from during that treatment available up to 1 January 2025
  • People who had a tissue sample (biopsy) taken between 1 January 2018 and 1 January 2025
  • People who have leftover tissue stored from a previous biopsy or surgery
  • People whose biopsy was taken less than one year before they started their cancer medication
  • People who are still alive must be able to sign a consent form allowing their stored tissue and data to be used for research

For Group 2 (people with advanced HCC — new participants):

  • People suspected of having HCC based on scans, or whose HCC has come back after previous treatment
  • People for whom a tissue biopsy is already planned as part of their standard medical care
  • People who, once HCC is confirmed by pathology, would be considered for some form of systemic (whole-body) cancer treatment (confirm with trial site)
  • People who are able to sign a consent form for the use of their tissue, blood samples, and data for research

For Group 3 (people with early-stage HCC — new participants):

  • People suspected of having HCC based on scans, or whose HCC has come back after previous treatment

  • People for whom surgery to remove the tumour or a procedure to destroy the tumour is already planned as part of their standard medical care

  • People who are able to sign a consent form for the use of their tissue, blood samples, and data for research

  • People already taking part in another clinical trial may still be eligible for this study, provided tissue and blood samples can be collected as required (confirm with trial site)


Who may not be able to join:

  • People whose liver function or general health is too poor to receive active treatment
  • People whose liver cancer has been confirmed by pathology to be a different type — such as a cancer of the bile ducts (cholangiocarcinoma) or cancer that has spread to the liver from elsewhere in the body
  • People whose planned treatment is something other than systemic (whole-body) medication or surgery/ablation — for example, those planned for procedures such as TACE, TARE, or a liver transplant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 016344225

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
4 March 2025
Est. completion
1 January 2029

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

Spatial orientation; TCR sharing; Antigen identification; Biomarker validation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov